Shabnam Shalapour, PhD
Department of Cancer Biology, Division of Discovery Science
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Cancer Biology and Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2010 | Charité - the Medical Faculty of Free University of Berlin, Berlin, DE, Doctor of Natural Sciences |
| 2003 | Heinrich-Heine University Düsseldorf, Düsseldorf, DE, Chemistry, Masters |
Postgraduate Training
| 2012-2018 | Postdoctoral Fellow (DFG and CRI-Irvington Fellow), Laboratory of Gene Regulation and Signal Transduction, University of California San Diego, San Diego, California |
Experience & Service
Faculty Academic Appointments
Project Scientist/Assistant Adjunct Professor, Department of Pharmacology, UC San Diego School of Medicine, San Diego, California, 2018 - 2020
Editorial Activities
Reviewer, Frontier in Immunology
Reviewer, Science Advances
Reviewer, Nature Communications
Reviewer, PNAS
Reviewer, Cells
Reviewer, JCI insight
Reviewer, eLife
Reviewer, Int J of Cancer
Reviewer, Nature
Honors & Awards
| 2022 - Present | MRA Team Science Award, The University of Texas MD Anderson Cancer Center |
| 2022 | Career Enhancement Program (CEP) Award, MD Anderson SPORE in Hepatocellular Carcinoma |
| 2021 - Present | Rising STARs Award, The University of Texas |
| 2021 | Career Enhancement Program (CEP) Award, The University of Texas MD Anderson Cancer Center |
| 2016 | USC-Pilot Project Young Investigator award, Keck School of Medicine of USC |
| 2015 | PCF (Prostate Cancer Foundation) Young Investigator award, Prostate Cancer Foundation (PCF) |
| 2014 - Present | CRI Irvington Postdoctoral Fellowship Award, Cancer Research Institute (CRI) |
| 2012 | German Research Foundation (DFG) Postdoctoral Fellowship, German Research Foundation (DFG) |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Deciphering Biological and Immunological Signatures of Diet-Induced MASH- and MetALD-Driven Hepatocellular Carcinoma. Invited. Research Exchange Lecture Series Spring 2025. Houston, Texas, US.
- 2024. Macronutrient composition drives differential “Immuno-Metabolic” responses dictating the mechanism of diet-induced cancer. Invited. Princess Margaret Joint Symposium in Cancer Metabolism. Houston, TX, US.
- 2024. Elucidating the mechanisms underlying the contradictory roles of IgA+ B cells in gastrointestinal cancers. Invited. 31.PRIME-TR, Research Seminar Series. Houston, Texas, US.
- 2024. Decoding the Impact of Macronutrients and alcohol on Host Metabolism and Immune Response in Diet-Induced Cancer. Invited. Energy Balance Research Seminar. Houston, Texas, US.
- 2024. Macronutrient Composition Drives Differential “Immuno-Metabolic” Responses Dictating the Mechanism of Diet-Induced Cancer. Invited. TMP Retreat - Next-Generation Pathology: Comprehensive Understanding of the Tumor Immune Neural Network. Houston, TX.
- 2024. Is liver tropism driven by diet? Immuno-metabolic dysregulation of liver by macronutrient composition fertilizes “liver” soil. Invited. CCSG Cancer Biology and Metastasis Program Annual Retreat and Workshop. Houston, Texas, US.
- 2024. Macronutrient composition drives differential Immuno-Metabolic responses dictating the mechanism of diet-induced cancers. Invited. MGH Center for Cancer Research Seminar Series. Houston, Texas, US.
- 2024. Dietary composition and response to immunotherapy. Invited. Seminar Series. Houston, Texas, US.
- 2023. Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Therapy. Invited. MD Anderson’s Precancer Atlas Seminar Series. Houston, Texas, US.
National Presentations
- 2024. Macronutrient composition dictates MASH-associated HCC immunosurveillance throughmicrobiota alteration and metabolic adaptation. Poster. San Diego, California, US.
- 2024. Macronutrient composition drives differential Immuno-Metabolic responses dictating the mechanism of diet-induced cancers. Invited. Seminar Series. Boston, MA.
- 2023. Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Therapy. Conference. Immuno-Oncology Translational Network (IOTN). Bethesda, MD, US.
- 2023. "Macronutrient composition regulation of nutrient sensing factors and neurotransmitters affects anti-tumor immunity and subsequently HCC development". Conference. The American Association of Immunologists, WA, US.
- 2023. Macronutrient Composition Regulation of Nutrient Sensing Factors and Neurotransmitters Affects Anti-Tumor Immunity and Subsequently HCC Development. Poster. American Association of Immunologists Annual Meeting. Washington, DC, US.
- 2022. Macronutrient composition, alcohol and HCC. Invited. IOTN-NIH Spring Meeting. Bethesda, Maryland, US.
- 2020. Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Therapy. Invited. HCC-TAG Conference. Park City, UT.
- 2019. Metabolism and Liver Cancer: From Mechanism to Treatment. Invited. Chicago, Illinois, US.
- 2015. Immunosuppressive B Cells and Antitumor Immunity. Invited. La Jolla Immunology Conference. La Jolla, California, US.
International Presentations
- 2025. Dietary Macronutrient Composition drives differential “Immuno-metabolic” responses dictating the mechanism of malignant transformation. Poster. 3rd Mitochondria Conference, DO.
- 2023. Session 'Immunotherapy and beyond' Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Therapy”. Invited. German Cancer Aid and the Mildred Scheel Foundation for Cancer Research, DE.
- 2023. Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Immunotherapy. Invited. 10th Mildred Scheel Cancer Conference, DE.
- 2023. Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Therapy. Conference. Molecular and Cellular Immunology of Metabolism, GR.
- 2023. Diet, Microbiome and Immune System Trialogue in Liver Cancer Development and Response to Therapy. Invited. Metabolomics and Human Health Gordon Research Conference. Ki, US.
- 2019. Macronutrient composition, alcohol and HCC. Invited. 17th ESBRA Congress. Lille, US.
- 2019. Macronutrient composition, alcohol and HCC. Invited. SignGene Symposium on Immunotherapy of Cancer. Neuruppin, DE.
- 2019. Tumor microenvironment and cancer. Poster. International Cancer Immunotherapy Conference (CICON). Paris, FR.
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | Humoral Immunity and Hepatic Immune Networks in Diet- and Alcohol-Associated Liver Cancer: Mechanisms of Tumor Progression and Immunotherapy Response |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP00024344 |
| Date: | 2025 - 2029 |
| Title: | Role of GRAIL in B cell tolerance and B-cell mediated inflammation |
| Funding Source: | NIH/NIAID |
| Role: | Co-I |
| ID: | 1R01AI183604-01A1 |
| Date: | 2025 - Present |
| Title: | Role of Diet-Induced Hepatocellular Carcinoma-Derived Serotonin in Regulating Immunological Synapse Formation and Anti-Tumor Immunity |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP00025524 |
| Date: | 2022 - 2023 |
| Title: | MD Anderson HCC SPORE Developmental Research Award |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Harnessing B cell checkpoints in melanoma |
| Funding Source: | Brigham, Women's Hospital, and The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2021 - 2022 |
| Title: | MD Anderson HCC SPORE Developmental Research Award |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | UT System Rising STARs Award |
| Funding Source: | UTHealth Houston |
| Role: | Co-I |
| Date: | 2019 - 2021 |
| Title: | Using chemotherapeutic drugs to augment antigen processing and presentation and render non-responsive tumors susceptible to PD-1 checkpoint inhibitors. Major Goals: To investigate how low-dose oxaliplatin renders tumors that are refractory to PD-1 blockade responsive to PD-1 checkpoint inhibitors and how to enable the clinical use of low-dose oxaliplatin as an adjuvant to PD-1:PD-L1 interaction inhibitors |
| Funding Source: | Keck School of Medicine of USC |
| Role: | PI |
| ID: | 59717 |
| Date: | 2018 - 2023 |
| Title: | Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA234128 |
| Date: | 2018 - 2023 |
| Title: | Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | U01CA233051 |
| Date: | 2018 - 2019 |
| Title: | Southern California Research Center for ALPD & Cirrhosis Pilot Project Grant |
| Funding Source: | NIAAA |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Role of IgA+ and CD8+ T cells in alcoholic steatohepatitis progression to cancer |
| Funding Source: | Southern California Research Center for ALPD and Cirrhosis |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Prostate Cancer Foundation (PCF) Young Investigator Award |
| Funding Source: | Prostate Cancer Foundation |
| Role: | PI |
| Date: | 2015 - 2017 |
| Title: | Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship |
| Funding Source: | University of San Diego |
| Role: | Key |
| Date: | 2015 - 2016 |
| Title: | Southern California Research Center for ALPD & Cirrhosis Pilot Project Grant |
| Funding Source: | NIAAA |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | German Research Foundation (DFG) Fellowship |
| Funding Source: | University of San Diego |
| Role: | Key |
Selected Publications
Peer-Reviewed Articles
- Dai, Y, Pan, X, Guo, S, Ji, S, Cao, S, Montierth, M, Jiang, Y, Chang, J, Shi, LM, Shalapour, S, Echeverria, GV, Yates, LR, Staaf, J, Lim, B, Yuan, Y, Wang, W. Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer. Cell Reports Medicine 7(2), 2026. e-Pub 2026. PMID: 41707645.
- Mahadevan KK, Maldonado AS, Li B, Bickert AA, Kapercyzk-Perdyan A, Kumbhar SV, Piya S, Sockwell A, Morse SJ, Arian K, Sugimoto H, Shalapour S, Hong DS, Heffernan TP, Maitra A, Kalluri R. Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40093186.
- Zhang P, Liu J, Lee A, Tsaur I, Ohira M, Duong V, Vo N, Watari K, Su H, Kim JY, Gu L, Zhu M, Shalapour S, Hosseini M, Bandyopadhyay G, Zeng S, Llorente C, Zhao HN, Lamichhane S, Mohan S, Dorrestein PC, Olefsky JM, Schnabl B, Soroosh P, Karin M. IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis. Cell Metab 36(10):2341-2354.e6, 2024. e-Pub 2024. PMID: 39317186.
- Luo X, McAndrews KM, Arian KA, Morse SJ, Boeker V, Kumbhar SV, Hu Y, Mahadevan KK, Church KA, Chitta S, Ryujin NT, Hensel J, Dai J, Dowlatshahi DP, Sugimoto H, Kirtley ML, LeBleu VS, Shalapour S, Simmons JH, Kalluri R. Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. J Control Release 374:550-562, 2024. e-Pub 2024. PMID: 39146981.
- Mahadevan KK, Dyevoich AM, Chen Y, Li B, Sugimoto H, Sockwell AM, McAndrews KM, Sthanam LK, Wang H, Shalapour S, Watowich SS, Kalluri R. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science 384(6703):eadh4567, 2024. e-Pub 2024. PMID: 38935717.
- Rundberg Nilsson AJS, Xian H, Shalapour S, Cammenga J, Karin M. IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance. Sci Adv 9(43):eadg5391, 2023. e-Pub 2023. PMID: 37889967.
- Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A 120(19):e2300706120, 2023. e-Pub 2023. PMID: 37126700.
- Mahadevan KK, Dyevoich AM, Chen Y, Li B, Sugimoto H, Sockwell AM, McAndrews KM, Wang H, Shalapour S, Watowich SS, Kalluri R. Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer. bioRxiv, 2023. e-Pub 2023. PMID: 36945457.
- Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang J, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. bioRxiv, 2023. e-Pub 2023. PMID: 36945365.
- Rundberg Nilsson A, Xian H, Shalapour S, Cammenga J, Karin M. IRF1 regulates self-renewal and stress-responsiveness to support hematopoietic stem cell maintenance. bioRxiv, 2023. e-Pub 2023. PMID: 36747722.
- Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov 12(11):2626-2645, 2022. e-Pub 2022. PMID: 36098652.
- De Marco M, Gauttier V, Pengam S, Mary C, Ranieri B, Basile A, Festa M, Falco A, Reppucci F, Cammarota AL, Acernese F, De Laurenzi V, Sala G, Brongo S, Miyasaka M, Shalapour S, Vanhove B, Poirier N, Iaccarino R, Karin M, Turco MC, Rosati A, Marzullo L. Concerted BAG3 and SIRPalpha blockade impairs pancreatic tumor growth. Cell Death Discov 8(1):94, 2022. e-Pub 2022. PMID: 35241649.
- Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-kappaB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A 118(8), 2021. e-Pub 2021. PMID: 33602823.
- Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab 2(10):1034-1045, 2020. e-Pub 2020. PMID: 32839596.
- Ryan ST, Zhang J, Burner DN, Liss M, Pittman E, Muldong M, Shabaik A, Woo J, Basler N, Cunha J, Shalapour S, Estrada MV, Karin M, Messer K, Howell S, Kane CJ, Jamieson CAM. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. J Transl Med 18(1):214, 2020. e-Pub 2020. PMID: 32466781.
- Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, Taniguchi K, Seki E, Harismendy O, Shalapour S, Karin M, Carter H, Font-Burgada J. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115(42):E9879-E9888, 2018. e-Pub 2018. PMID: 30287485.
- Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, Wong J, Ding S, Seki E, Schnabl B, Hevener AL, Greenberg HB, Kisseleva T, Karin M. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560(7717):198-203, 2018. e-Pub 2018. PMID: 30046112.
- Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell 33(6):1061-1077.e6, 2018. e-Pub 2018. PMID: 29894692.
- Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551(7680):340-345, 2017. e-Pub 2017. PMID: 29144460.
- Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, Karin M. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 35(20):2634-44, 2016. e-Pub 2016. PMID: 26364612.
- Shalapour S, Karin M. Fatty Acid-Induced T Cell Loss Greases Liver Carcinogenesis. Cell Metab 23(5):759-61, 2016. e-Pub 2016. PMID: 27166937.
- Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SR, McGeough MD, Ellisman MH, Seki E, Gustafsson AB, Hoffman HM, Diaz-Meco MT, Moscat J, Karin M. NF-kappaB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell 164(5):896-910, 2016. e-Pub 2016. PMID: 26919428.
- Font-Burgada J, Shalapour S, Ramaswamy S, Hsueh B, Rossell D, Umemura A, Taniguchi K, Nakagawa H, Valasek MA, Ye L, Kopp JL, Sander M, Carter H, Deisseroth K, Verma IM, Karin M. Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer. Cell 162(4):766-79, 2015. e-Pub 2015. PMID: 26276631.
- Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521(7550):94-8, 2015. e-Pub 2015. PMID: 25924065.
- Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, Taniguchi K, Feng Y, Fearon E, Grivennikov SI, Karin M. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41(6):1052-63, 2014. e-Pub 2014. PMID: 25526314.
- Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A 111(41):14776-81, 2014. e-Pub 2014. PMID: 25267627.
- Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN, Karin M. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 20(1):133-44, 2014. e-Pub 2014. PMID: 24910242.
- He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, Koike K, Karin M. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155(2):384-96, 2013. e-Pub 2013. PMID: 24120137.
- Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M. An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 27(13):1435-40, 2013. e-Pub 2013. PMID: 23796898.
- Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G, Prada J, von Stackelberg A, Seeger K, Shalapour S. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin Cancer Res 19(6):1445-57, 2013. e-Pub 2013. PMID: 23357978.
- Shalapour S, Deiser K, Kuhl AA, Glauben R, Krug SM, Fischer A, Sercan O, Chappaz S, Bereswill S, Heimesaat MM, Loddenkemper C, Fromm M, Finke D, Hammerling GJ, Arnold B, Siegmund B, Schuler T. Interleukin-7 links T lymphocyte and intestinal epithelial cell homeostasis. PLoS One 7(2):e31939, 2012. e-Pub 2012. PMID: 22384106.
- Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J, Henze G, von Stackelberg A, Seeger K. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 96(11):1627-35, 2011. e-Pub 2011. PMID: 21828124.
- Hof J, Krentz S, van Schewick C, Korner G, Shalapour S, Rhein P, Karawajew L, Ludwig WD, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 29(23):3185-93, 2011. e-Pub 2011. PMID: 21747090.
- Czeh M, Loddenkemper C, Shalapour S, Schon C, Robine S, Goldscheid E, Stein H, Schuler T, Willimsky G, Blankenstein T. The immune response to sporadic colorectal cancer in a novel mouse model. Oncogene 29(50):6591-602, 2010. e-Pub 2010. PMID: 20818425.
- Shalapour S, Deiser K, Sercan O, Tuckermann J, Minnich K, Willimsky G, Blankenstein T, Hammerling GJ, Arnold B, Schuler T. Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo. Eur J Immunol 40(9):2391-400, 2010. e-Pub 2010. PMID: 20690180.
- Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T. Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. J Mol Med (Berl) 88(3):249-65, 2010. e-Pub 2010. PMID: 20155409.
- Giese A, Kirschner-Schwabe R, Blumchen K, Wronski L, Shalapour S, Prada J, Driever PH, Brauer M, Schuelke M, Henze G, Seeger K. Prenatal manifestation of pancytopenia in Pearson marrow-pancreas syndrome caused by a mitochondrial DNA deletion. Am J Med Genet A 143A(3):285-8, 2007. e-Pub 2007. PMID: 17219391.
- Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Buhrer C, Henze G, Seeger K, Wellmann S. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12(18):5526-32, 2006. e-Pub 2006. PMID: 17000689.
Review Articles
- Bod L, Shalapour S. B cells spatial organization defines their phenotype and function in cancer "Tell me with whom you consort, and I will tell you who you are" - Goethe. Curr Opin Immunol 91:102504, 2024. e-Pub 2024. PMID: 39547092.
- Karin M, Shalapour S. Regulation of antitumor immunity by inflammation-induced epigenetic alterations. Cell Mol Immunol 19(1):59-66, 2022. e-Pub 2022. PMID: 34465885.
- Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 35(11-12):787-820, 2021. e-Pub 2021. PMID: 34074695.
- Shalapour S, Karin M. The neglected brothers come of age: B cells and cancer. Semin Immunol 52:101479, 2021. e-Pub 2021. PMID: 34215491.
- Shalapour S, Karin M. Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers. Annu Rev Immunol 38:649-671, 2020. e-Pub 2020. PMID: 32040356.
- Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, Inflammation and Colorectal Cancer. Cells 9(3), 2020. e-Pub 2020. PMID: 32143413.
- Shalapour S, Karin M. Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation. Immunity 51(1):15-26, 2019. e-Pub 2019. PMID: 31315033.
- Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metab 29(1):18-26, 2019. e-Pub 2019. PMID: 30449681.
- Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347-55, 2015. e-Pub 2015. PMID: 26325032.
Other Articles
- Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M Author Correction: Inflammation-induced IgA(+) cells dismantle anti-liver cancer immunity. Nature 561(7721):E1, 2018. PMID: 29973714.
- Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M Erratum: Inflammation-induced IgA(+) cells dismantle anti-liver cancer immunity. Nature 552(7685):430, 2017. PMID: 29168501.
Letters to the Editor
- Wang M, Jarmusch AK, Vargas F, Aksenov AA, Gauglitz JM, Weldon K, Petras D, da Silva R, Quinn R, Melnik AV, van der Hooft JJJ, Caraballo-Rodriguez AM, Nothias LF, Aceves CM, Panitchpakdi M, Brown E, Di Ottavio F, Sikora N, Elijah EO, Labarta-Bajo L, Gentry EC, Shalapour S, Kyle KE, Puckett SP, Watrous JD, Carpenter CS, Bouslimani A, Ernst M, Swafford AD, Zuniga EI, Balunas MJ, Klassen JL, Loomba R, Knight R, Bandeira N, Dorrestein PC. Mass spectrometry searches using MASST. Nat Biotechnol 38: 23-26, 2020.
- Prada J, Shalapour S, Pfau M, Henze G, Seeger K. The serotonin receptor-antagonist ondansetron induces significant increases in the expression of interferon-gamma which correlate with antiproliferative properties in the acute lymphoblastic leukaemia cell line REH. Scand J Immunol 76: 519-20, 2012.
- Prada J, Shalapour S, Pfau M, Henze G, Seeger K. Antiproliferative effect of the serotonin receptor antagonist ondansetron in the acute lymphoblastic leukemia cell line REH. Acta Oncol 50: 591-2, 2011.
- Bastian L, Einsiedel HG, Henze G, Seeger K, Shalapour S. The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia 25: 359-61, 2011.
Patient Reviews
CV information above last modified June 17, 2026